AstraZeneca's blood thinner Brilinta is officially one step closer to living up to the British pharma's $3.5 billion ambitions. The FDA has handed down an approval for long-term use of the drug in patients who have previously suffered heart attacks, a label expansion that will keep sales coming beyond the first year of therapy.
Just in time for flu season, AstraZeneca granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan. The live attenuated vaccine, delivered nasally, went through Phase III trials in Japanese children, and a regulatory submission is being prepared for Japan.
Before September is out, AstraZeneca predicts it'll have a label expansion in hand for growth prospect Brilinta, based on results of its PEGASUS study. And when Brilinta gets that go-ahead, its sales force will be raring to go.
Valeant has long been working to beef up its presence in the fast-growing dermatology space, and now, it's made its way into contention in the next-gen psoriasis field with a deal for AstraZeneca prospect brodalumab. The question, though, is whether it can get that candidate in the game.
Three months after Amgen washed its hands of the psoriasis drug brodalumab, its development partner AstraZeneca has found the exit door as well. The pharma giant auctioned off the Phase III-complete therapy to the wheeler dealers at Valeant in exchange for $100 million upfront, $170 million in prelaunch milestones and another $175 million in sales bonuses.
Earlier this year, AstraZeneca touted positive Brilinta (ticagrelor) data from its PEGASUS trial, which found that long-term use of the drug plus aspirin helped prevent heart attacks, strokes and cardiovascular death in post heart-attack patients--and did so better than long-term aspirin plus placebo. And now, AstraZeneca is armed with new details from the study, showing that stopping Brilinta therapy too soon can heighten risks of those very events, helping make the case for long-term use of the drug.
No one wants to talk about constipation. Except AstraZeneca. On national television. To the tune of almost $10 million in media spending since late June, according to real-time TV ad tracker iSpot.tv.
Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $80 million from a syndicate that includes a group of high-profile crossover investors.
AstraZeneca has filled the vacancy at the head of its R&D organization. Sean Bohen is set to take up the post next month after being persuaded to swap a position at the heart of early-stage R&D at Genentech for a chance to guide AstraZeneca's late-phase hopefuls toward approval.
AstraZeneca has struck its fourth immuno-oncology deal in as many weeks. The latest deal in the flurry of activity sees AstraZeneca hook up with Peregrine Pharmaceuticals to add another study to the burgeoning list of PD-L1 checkpoint inhibitor combination trials.